Authors | Year | ICI | n | Biomarker | Level of evidence | PFS | OS |
---|---|---|---|---|---|---|---|
Clinical findings | |||||||
 Conforti et al. [26] | 2018 | ICI single agent therapy | 11,351 | male gender | 2A | NS | + |
 Conforti et al. [27] | 2019 | PD-L1/PD-1 inhibitor + chemotherapy | 4923 | female gender | 2A | + | + |
 Kawachi et al. [28] | 2020 | pembrolizumab | 213 | pleural effusion | 2B | – | NS |
ECOG PS < 2 | 2B | + | NS | ||||
 Naqash et al. [29] | 2020 | nivolumab | 531 | irAE | 2B | + | + |
ECOG PS < 2 | 2B | + | + | ||||
ICI duration > 3 months | 2B | + | + | ||||
 Dall’Olio et al. [30] | 2020 | immunotherapy | 3600 | ECOG PS ≥ 2 | 2A | – | – |
 Cortellini et al. [31] | 2020 | PD-1/PD-L1 inhibitors | 1070 | BMI ≥ 25 kg/m^2 | 3B | + | + |
 Shepshelovich et al. [32] | 2019 | various assessments | 25,439 | BMI ≥ 40 / <  18,5 kg/m^2 | 2A | NS | – |
 Magri et al. [33] | 2019 | nivolumab | 46 | weight loss before treatment > 5% | 2B | NS | – |
 Kang et al. [34] | 2018 | PD-1/PD-L1 inhibitors | 51 | pleural or pericardial metastasis | 3B | – | NS |
 Adachi et al. [35] | 2020 | nivolumab | 296 | driver mutation positivity | 3B | – | NS |
CRP ≥ 1 mg/dL | 3B | – | NS | ||||
liver metastasis | 3B | – | NS | ||||
pleural effusion | 3B | – | NS | ||||
ALI ≥ 18 | 3B | + | NS | ||||
baseline steroid use | 3B | – | NS | ||||
 Reck et al. [36] | 2019 | ABCP | 1202 | liver metastasis | 1A | + | + |
 Sridhar et al. [37] | 2019 | Durvalumab | 569 | liver metastasis | 1A | – | – |
 Scott et al. [38] | 2018 | nivolumab | 210 | baseline steroid use | 3B | NS | – |
 Fuca et al. [39] | 2019 | PD-1/PD-L1 inhibitors | 151 | baseline steroid use | 3B | – | – |
 Arbour et al. [40] | 2018 | PD-1/PD-L1 inhibitors | 640 | baseline steroid use | 3B | – | – |
 Routy et al. [41] | 2018 | PD-1/PD-L1 inhibitors | 379 | antibiotic use (60 days before thx) | 2B | – | – |
 Derosa et al. [42] | 2018 | PD-1/PD-L1 inhibitors | 239 | antibiotic use (30 days before thx) | 3B | NS | – |
 Ahmed et al. [43] | 2018 | PD-1/PD-L1 inhibitors | 60 | broad spectrum antibiotics | 2B | – | NS |
 Chalabi et al. [44] | 2020 | atezolizumab + docetaxel | 1512 | antibiotic use | 1A | NS | – |
 Hakozaki et al. [45] | 2020 | nivolumab, pembrolizumab or atezolizumab | 90 | decreased Ruminococcaceae UCG 13 and Agathobacter | 2B | – | – |
Laboratory values | |||||||
 Cao et al. [46] | 2018 | nivolumab | 1225 | NLR ≥ 5 | 3A | – | – |
 Zhang et al. [47] | 2020 | ICI therapy 2nd-line | 74 | NLR ≥ 3 | 3B | NS | NS |
 Iivanainen et al. [48] | 2019 | PD-1/PD-L1 inhibitors | 160 | NLR > 2,65 | 2B | – | – |
CRP ≥ 10 mg/mL | 2B | – | – | ||||
 Liu et al. [49] | 2019 | nivolumab | 44 | NLR ≤ 3.07 | 3B | + | + |
SII ≤ 603.5 | 3B | + | + | ||||
PLR ≤ 144 | 3B | + | + | ||||
 Mezquita et al. [50] | 2018 | PD-1/PD-L1 inhibitors | 628 | positive LIPI | 2B | NS | – |
LDH > UNL | 2B | NS | + | ||||
 Passaro et al. [51] | 2020 | nivolumab | 53 | Gr-MDSC < 6 cells/μl | 2B | + | + |
NC < 5840/μl | 2B | + | + | ||||
eosinophils > 90/μl | 2B | + | + | ||||
NLR < 3 | 2B | + | + | ||||
 Tanizaki et al. [52] | 2018 | nivolumab | 134 | ALC > 1000/μ | 3B | + | NS |
AEC > 150/μL | 3B | + | NS | ||||
ANC > 7500/μL | 3B | – | – | ||||
 Zhang et al. [53] | 2019 | PD-1/PD-L1 inhibitors | 1136 | LDH > UNL | 3A | + | + |
 Naqash et al. [54] | 2018 | nivolumab | 87 | CRP > 50 mg/L | 2B | NS | – |
NLR > 6,5 | 2B | NS | – | ||||
PNI < 31,5 | 2B | NS | – | ||||
Immunohistochemistry and genetic parameters | |||||||
 Okuma et al. [55] | 2018 | nivolumab | 39 | sPD-L1 > 3357 ng/mL | 2B | NS | + |
 Costantini et al. [56] | 2018 | nivolumab | 43 | low sPD-L1 | 2B | + | + |
 Shibaki et al. [57] | 2020 | nivolumab, pembrolizumab | 235 | low serum VEGF | 3B | + | + |
 Wang et al. [58] | 2019 | PD-1/PD-L1 inhibitors | 98 | bTMB > 6 | 3B | + | NS |
 Rizvi et al. [59] | 2020 | durvalumab vs. durvalumab + tremelimumab vs. chemo | 1118 | bTMB ≥20 mut/mb | 1B | NS | + |
 Paz-Ares et al. [60] | 2019 | pembrolizumab + chemo vs. chemo | 605 | tTMB | 1A | NS | NS |
 Herbst et al. [61] | 2019 | pembrolizumab vs. platinum-based chemo | 1274 | KRAS & pembrolizumab | 1B | + | + |
 Gadgeel et al. [62] | 2019 | pembrolizumab+premetrexed+platinum vs. placebo+premetrexed+platinum | 616 | KRAS & pembrolizumab +chemo | 1B | + | + |
 Skoulidis et al. [63] | 2018 | PD-1/PD-L1 inhibitors | 1208 | STK11/LKB1 | 2B | – | – |
 Arbour et al. [64] | 2019 | ICI inhibitors vs. chemotherapy | 330 | KEAP1/NFE2L2 | 2B | NS | – |
 Cho et al. [65] | 2020 | pembrolizumab vs. platinum-based chemo | 1274 | STK11 or KEAP1 | 1B | NS | NS |
 Bratman et al. [66] | 2020 | pembrolizumab | 94 | low baseline ct-DNA concentration | 2A | + | + |
 Zulato et al. [67] | 2020 | ICI therapy | 34 | new KRAS mutation becoming apparent after 3–4 weeks | 2B | – | – |